Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Moll, Guido  [Clear All Filters]
2023
Chinnadurai R, Viswanathan S, Moll G. Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis. Front Immunol. 2023;14:1192636.
Uwazie CC, Pirlot BM, Faircloth TU, Patel M, Parr RN, Zastre HM, Hematti P, Moll G, Rajan D, Chinnadurai R. Effects of Atrazine exposure on human bone marrow-derived mesenchymal stromal cells assessed by combinatorial assay matrix. Front Immunol. 2023;14:1214098.
2022
Moll G, Ankrum JA, Olson SD, Nolta JA. Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products. Stem Cells Transl Med. 2022;11(1):2-13.
2021
Drzeniek N, Mazzocchi A, Schlickeiser S, Forsythe S, Moll G, Geissler S, Reinke P, Gossen M, Gorantla VSaradhi, Volk H-D, et al. Bio-instructive hydrogel expands the paracrine potency of mesenchymal stem cells. Biofabrication. 2021.
2019
Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringdén O, Volk H-D, Geissler S, Reinke P. Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends Mol Med. 2019.
2014
Moll G, Hult A, von Bahr L, Alm JJ, Heldring N, Hamad OA, Stenbeck-Funke L, Larsson S, Teramura Y, Roelofs H, et al. Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells?. PLoS One. 2014;9(1):e85040.